Global Anti-Infectives Market to Reach $103 Billion by 2015: Report

The global market for anti-infective drugs, which mainly includes antibacterials, antivirals, antifungals, and vaccines, is projected to exceed $103 billion by the year 2015, according to a new report from Global Industry Analysts Inc., a San Jose, Calif.-based market research and publishing firm.

The report, titled "Anti-Infectives: A Global Strategic Business Report," says factors driving sales include the introduction of novel therapeutics for drug-resistant bacteria, increasing incidence of severe fungal infections, the potential launch of new antiviral agents, and the introduction of new drugs in the HIV market. Anti-infectives are indicated for the treatment of infections caused by bacteria, fungi, protozoa, prions, and parasites. Other causative agents responsible for developing infectious disorders include chlamydiae, mycoplasmas, worms, rickettsiae, helminths, and yeast.

Antibacterials represent the largest segment of the anti-infectives market globally, and in the antibacterials class, sales are led by cephalosporins, followed by macrolides, fluoroquinolones, and penicillins, the report notes.

Antivirals represent another major anti-infective drug class. Some of the major growth drivers for anti-virals include increased awareness of the disease and its progression, development of novel drug classes, limited generic competition, increased R&D investments fuelled by the growth of drug resistance among patients, and reduction of R&D costs through genomics. According to the report, antiviral drugs are expected to register the fastest growth rate, compared to the other drug classes, including antibacterials, antifungals, and others such as vaccines.

The report provides a comprehensive review of the anti-infectives market by therapeutic class, growth drivers, growth inhibitors, research and development, product introductions, product approvals, and recent industry activity. Key players profiled in the study include Abbott Laboratories, Alcon Pharmaceuticals Ltd., Astellas Pharma Inc., AstraZeneca Plc, Bayer HealthCare AG, Bristol-Myers Squibb Co., Boehringer Ingelheim, Cubist Pharmaceuticals Inc., Daiichi Sankyo Company Ltd., Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline Plc, F. Hoffmann-La Roche, Ltd., Johnson & Johnson, Merck & Co. Inc, Novartis AG, Pfizer Inc., Sanofi-Aventis SA, Schering-Plough Corp., and Wyeth Pharmaceuticals Inc., among others.

The study provides sales for regions including the United States, Japan, Europe, and the rest of the world collectively. The report also analyzes the market by therapeutic classes, including antibacterials, antivirals, antifungals, and others. Antibacterials are further broken down by drug classes such as Cephalosporins, Penicillins, Fluoroquinolones, Macrolides, and Others. For more details, visit

Download Center

HTML - No Current Item Deck
  • Free Safety Management Software Demo

    IndustrySafe Safety Management Software helps organizations to improve safety by providing a comprehensive toolset of software modules to help businesses identify trouble spots; reduce claims, lost days, OSHA fines; and more.

  • Comply with OSHA’s Electronic Recordkeeping Requirements

    Collect relevant incident data and generate accurate OSHA 300, 300A, and 301 regulatory reports, including 300A CSV files for easy electronic submission to OSHA.

  • Complete Online Safety Training Courses

    Deliver state-of-the art, online safety training courses to your organization with IndustrySafe Training Management Software. Generate reports to track training compliance and automatically notify learners of upcoming or overdue classes.

  • Easy to Use Safety Inspection App

    Conduct inspections on the go with IndustrySafe’s mobile app. Complete safety audits at job sites and remote locations—with or without web access.

  • Track Key Safety Performance Indicators

    IndustrySafe’s Dashboard Module allows organizations to easily track safety KPIs and metrics. Gain increased visibility into your business’ operations and safety data.

  • Industry Safe
comments powered by Disqus